B-Cell Acute Lymphocytic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry (COG Protocol)
Ordering Recommendation

Detect minimal residual disease in patients of all ages previously diagnosed with B-ALL.

Flow Cytometry
1-2 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Bone marrow. Whole blood: Green (Sodium Heparin) or Lavender (EDTA). 
Specimen Preparation
Transport 2 mL heparinized bone marrow (Min: 1.0 mL*) OR 3 mL whole blood (Min: 1mL*) 
Storage/Transport Temperature
Room temperature. Also acceptable: Refrigerated. Specimen should be received within 24 hours of collection for optimal cell viability. 
Unacceptable Conditions
Clotted or hemolyzed specimens. 
Provide specimen source, CBC, Wright stained smear (if available), clinical history, differential diagnosis.
Follow up: If previous leukemia/lymphoma phenotyping was performed at another lab, the outside flow cytometry report and histograms (if possible) should accompany the specimen. 
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable 
Reference Interval
By Report
Interpretive Data
Refer to report.

Compliance Statement A: For laboratory developed tests using a manufacturer labeled ASR as the reagent providing the specificity of the assay. Analyte Specific Reagent. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, the FDA has determined that such clearance or approval is not necessary.

This assay is a minimal residual disease assessment of B-ALL by flow cytometry.

Available Markers*: CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16

*Not all markers will be reported in all cases.

DAY 8 Peripheral Blood sample will have CD10, CD19, CD20, CD34, CD45, and Syto 16 run and reported. (6 markers total).

Day 29 Bone Marrow sample will have CD3, CD9, CD10, CD13, CD19, CD20, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16 run and reported. (13 markers total).

The report will include a pathologist interpretation and a marker interpretation range corresponding to CPT codes of 2-8 markers, 9-15 markers interpreted. Charges apply per marker.
Hotline History
View Hotline History
CPT Code(s)
88184; 88185; each additional marker 88187 or 88188.
Component Test Code*Component Chart NameLOINC
3000737Number of Markers19099-1
3000738B-ALL MRD (COG Protocol) Interpretation45267-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Acute Leukemia Follow up Phenotyping by Flow Cytometry
  • Follow-Up Phenotyping
  • Hematopoietic neoplasms monitoring
  • Leukemia/Lymphoma Evaluation Panel
  • Leukemia/Lymphoma Phenotyping, Comprehensive - Bone Marrow
  • Leukemia/Lymphoma Phenotyping, Comprehensive - Miscellaneous
  • Leukemia/Lymphoma Phenotyping, Comprehensive - Whole Blood